Indication

Anaemia with chronic kidney disease

RAG rating

Red

Document type

Decision document

Place

Hertfordshire and West Essex ICB

Output type

Pharmacy / Prescribing

Document

Download

Roxadustat

HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)

Roxadustat for the treatment of symptomatic anaemia associated with

chronic kidney disease

RED

Recommended for restricted prescribing by specialist only.

Not recommended for primary care prescribing.

Name generic (trade) Roxadustat

What it is Hypoxia-inducible factor, prolyl hydroxylase inhibitor (HIF-PHI).

Indication Licensed for the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease

Date decision last revised September 2022

Decision status Final

NICE / SMC Guidance NICE TA 807 recommended

HWE APC recommendation:

Roxadustat is recommended for restricted use as an option for the treatment of adult patients with symptomatic anaemia associated with chronic kidney disease in line with the recommendations in NICE TA 807

Review date: The recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.